Early research (Phase 1)Study completedNCT00657683
What this trial is testing
A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age
Who this might be right for
Invasive Group B Streptococcus (GBS) Disease
Novartis Vaccines 65